Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database
Teresa A Simon,John H Simon,Erin G Heaning,Andres Gomez-Caminero,Jahan P Marcu
DOI: https://doi.org/10.2147/DHPS.S391857
2023-01-29
Drug, Healthcare and Patient Safety
Abstract:Teresa A Simon, 1 John H Simon, 1 Erin G Heaning, 1 Andres Gomez-Caminero, 1 Jahan P Marcu 1, 2 1 Physicians Research Center, LLC, Toms River, NJ, USA; 2 Marcu Enterprises, Jersey City, NJ, USA Correspondence: Teresa A Simon, Physicians Research Center, LLC, Toms River, NJ, 08753, USA, Tel +732 818-7900, Fax +732 557-0217, Email Purpose: The aim of this study was to characterize the frequency of adverse effects where delta-8 tetrahydrocannabinol (D8-THC) was identified as a possible suspect drug in the FDA Adverse Event Reporting System (FAERS) database. Methods: A case-series design was used. Results: A total of 183 cases listed D8-THC as a suspect drug in FAERS as of June 30, 2021. The most common events included dyspnea, respiratory disorder, and seizure. The reporting odds ratios were consistently and significantly greater than 2, a 2-fold increase from 2019 to 2021, indicating a potential safety signal. Conclusion: The first report of D8-THC, in the FAERS database, as a suspect drug appears to be in 2011. Overall, there are 183 total cases listing D8-THC as a suspect drug in the FAERS database as of June 30, 2021. Of the 183 cases, most were respiratory in nature. Keywords: cannabis, hemp-derived, safety, adverse effects, public health, cannabinoid, delta-8 tetrahydrocannabinol, hemp, adverse event There exists a lack of nationally representative, real-world data on the benefits and risks associated with hemp-derived products. This study aims to address this gap by identifying the unexpected medical problems for consumers of these products. In total, this study identified 183 cases which listed D8-THC as a suspect drug in the FDA Adverse Event Reporting System (FAERS) database. The most common adverse events included dyspnea, respiratory disorders, and seizures. Future work focusing on reliable, comprehensive safety data will promote progress in identifying risk of hemp-derived products and making them safer for consumers. In the United States, you can walk by shops and kiosks that have stacks of delta-8-tetrahydrocannabinol (D8-THC) products on their shelves. This ingredient is an isomer of delta-9-tetrahydrocannabinol (D9-THC) the well-known psychoactive ingredient in cannabis. D8-THC and other D9-THC isomer products have mysteriously flooded the market with confusing label information while resembling commercially available food products. The products are often characterized as hemp-derived products, meaning the main ingredient is artificially derived (aka synthesized or semi-synthesized) from cannabidiol (CBD) that is sourced from hemp. If asked, a shopkeeper may state that D8-THC and D9-THC are reported to have similar pharmacological activities. 1 Limited evidence from basic and clinical research suggests that D8-THC can be less potent than D9-THC at creating a cannabis-like high. 2 Unfortunately, hemp-derived products containing D8-THC and other isomers may have a greater probability of contamination or adulteration due to the synthetic processing and a lack of regulatory requirements, as compared to medical or adult-use cannabis products from state licensed operators. Many hemp operators (ie, cultivators, manufacturers, distributors, etc.) in the United States argue that the Agricultural Improvement Act of 2018 (aka the Hemp Farm Bill) created a loophole for THC "rich" compounds to be considered as "hemp products" and not "cannabis" products. 3 This seems to have allowed privileges to any entity wishing to create and distribute drugs that they claim are derived from CBD. 3 According to legal experts, the intention of the 2018 Hemp Farm Bill was to allow farmers to produce industrial hemp products (ie, textiles, fuel, and largely other non-consumables ) and was not intended to allow the sale of products that are laced with psychotropic substances derived from CBD as the reactant. 4 In December 2018, congressional approval of the Hemp Farm Bill amended the federal Controlled Substances Act to exclude hemp from the Schedule I definition of marijuana. Hemp is being defined as cannabis plants and products containing less than 0.3% THC in the United States. The statute remains silent on D8-THC and other isomers. The legislation does not explicitly state that certain isomers of THC are still Schedule I or which THC-isomer products exceed the 0.3% THC limit. Under this "0.3.% rule", hemp edibles can exceed the THC limit imposed for cannabis edibles (eg, 10mg THC maximum in most jurisdictions for cannabis products), as hemp is determined by the percent weight of THC – not a specific amount per dose or unit. 5 Basically, you may be able to buy more edible THC at a gas stat -Abstract Truncated-